Chemotherapy-induced Nausea and Vomiting Clinical Trial
Official title:
PUCE Study: Prevention of Unmitigated Chemotherapy-induced Emesis
Chemotherapy-induced nausea and vomiting (CINV) remains a major obstacle to patient care and continues to decrease quality of life. Despite the addition of medications and antiemetic regimens, doctors' ability to control CINV is still inadequate: even moderately-emetogenic chemotherapy regimens cause roughly 20% of patients to have vomiting and over 40% to experience significant nausea. In this study, the investigators test a transcranial vibrating system that has shown great promise at reducing nausea and vomiting. .
Chemotherapy-induced nausea and vomiting (CINV) remains a major obstacle to cancer patient care despite numerous medications being available to prevent and treat CINV. CINV decreases quality of life in roughly one third of patients receiving highly emetogenic chemotherapy. In addition, roughly half to two thirds of all patients receiving chemotherapy require rescue anti-emetic medications despite being given guideline-based prophylactic anti-emetics.The anti-emesis armamentarium continues to grow with new medications, including olanzapine and fosaprepitant, being studied in recent years. However, despite the addition of these medications and guideline-based antiemetic regimens, the ability to control CINV is still inadequate as even moderately-emetogenic chemotherapy regimens cause roughly 20% of patients to have vomiting and over 40% to experience significant nausea. In this study, the investigators aim to test a new transcranial vibrating system that has shown promise in phase I studies for treating dizziness, motion sickness and nausea. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04054193 -
Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)
|
Phase 4 | |
| Recruiting |
NCT04430361 -
the Efficacy and Safety of 5-HT3 Receptor Antagonist, Dexamethasone or Megestrol Acetate Dispersible Tablets in the Control of Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy
|
Phase 2 | |
| Recruiting |
NCT03668639 -
Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin
|
Phase 2/Phase 3 | |
| Completed |
NCT02285647 -
An Open-Label, Randomized, Pivotal, Bioequivalence Study of Oral and Intravenous Rolapitant
|
Phase 1 | |
| Terminated |
NCT01874119 -
Fosaprepitant for N/V With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell Carcinoma
|
Phase 2 | |
| Completed |
NCT01757210 -
A Study to Evaluate the Safety and Efficacy of Aprepitant (MK0869) for Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients
|
N/A | |
| Completed |
NCT01442376 -
Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients
|
Phase 3 | |
| Withdrawn |
NCT00891761 -
A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy
|
Phase 3 | |
| Completed |
NCT01031498 -
Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting
|
Phase 2 | |
| Terminated |
NCT02519842 -
Efficacy and Safety Study of Fosaprepitant (MK-0517) Plus Ondansetron Versus Ondansetron Alone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-044)
|
Phase 3 | |
| Recruiting |
NCT03232541 -
The Effects of Acupuncture and the Therapist´s Communication on Chemotherapy Induced Nausea and Vomiting
|
N/A | |
| Completed |
NCT02909478 -
Aprepitant Without Steroid in Preventing Chemotherapy-induced Nausea and Vomiting in Patients With Colorectal Cancer
|
Phase 3 | |
| Terminated |
NCT03237611 -
Low Dose Aprepitant for Patients Receiving Carboplatin
|
Phase 2 | |
| Completed |
NCT03649230 -
Observational Study on the Use of Akynzeo® in Patients Receiving HEC
|
||
| Not yet recruiting |
NCT02933099 -
Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting
|
Phase 3 | |
| Completed |
NCT02557035 -
An Efficacy and Safety Study of Intravenous Palonosetron Administered as an Infusion and as a Bolus for the Prevention of Nausea and Vomiting
|
Phase 3 | |
| Completed |
NCT00787566 -
Phase 2 Study of Efficacy, Tolerability, and Safety of Intranasal Granisetron for Chemo-Induced Nausea and Vomiting
|
Phase 2 | |
| Completed |
NCT06121414 -
Effectiveness of Laserpuncture and Standard Antiemetic on RINVR Scores in Adolescent Patients Undergoing Chemotherapy
|
N/A | |
| Completed |
NCT04918069 -
Capsaicin to Prevent Delayed Chemotherapy Induced Nausea and Vomiting (CapCIN)
|
Phase 2 | |
| Recruiting |
NCT05851625 -
Efficacy of Ear Acupuncture in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients
|
N/A |